[Sugammadex: a new approach to muscle relaxation and its reversal].
Duvaldestin
P
P
D000732:Androstanols / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D015195:Drug Design; D006801:Humans; D009119:Muscle Contraction / Q000187:drug effects*; D009126:Muscle Relaxation / Q000187:drug effects*; D019148:Neuromuscular Blockade / Q000009:adverse effects; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D010243:Paralysis / Q000139:chemically induced / Q000188:drug therapy; D011183:Postoperative Complications / Q000139:chemically induced / Q000188:drug therapy; D000077123:Rocuronium; D000077122:Sugammadex; D014673:Vecuronium Bromide / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D047408:gamma-Cyclodextrins / Q000494:pharmacology* / Q000627:therapeutic use
D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D014673:Vecuronium Bromide; D000077123:Rocuronium